

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CD8

RRID:AB_2738801

Type: Antibody

Proper Citation

BD Biosciences Cat# 564422, RRID:AB_2738801

Antibody Information

URL: http://antibodyregistry.org/AB_2738801

Proper Citation: BD Biosciences Cat# 564422, RRID:AB_2738801

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD8

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: 53-6.7

Antibody ID: AB_2738801

Vendor: BD Biosciences

Catalog Number: 564422

Record Creation Time: 20231110T033524+0000

Record Last Update: 20260829T212907+0000

Ratings and Alerts

No rating or validation information has been found for CD8.

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Huang C, et al. (2025) Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma. *Cancer discovery*, 15(12), 2450.

Palmer R, et al. (2025) Spatially Resolved Immune Profiling of the Murine Lung Using In Vivo Labeling and Spectral Cytometry. *Current protocols*, 5(12), e70276.

Tsai PJ, et al. (2024) PTEN acts as a crucial inflammatory checkpoint controlling TLR9/IL-6 axis in B cells. *iScience*, 27(7), 110388.

Franzolin G, et al. (2024) PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. *Cancer immunology research*, 12(9), 1286.

Darragh LB, et al. (2024) Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs. *Med (New York, N.Y.)*, 5(3), 254.

Piper M, et al. (2023) Simultaneous targeting of PD-1 and IL-2R?? with radiation therapy inhibits pancreatic cancer growth and metastasis. *Cancer cell*, 41(5), 950.

Tichet M, et al. (2023) Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. *Immunity*, 56(1), 162.

Gadwa J, et al. (2023) Selective targeting of IL2R?? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. *Cell reports. Medicine*, 4(8), 101150.

Du H, et al. (2023) Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. *iScience*, 26(7), 107090.

Huseni MA, et al. (2023) CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. *Cell reports. Medicine*, 4(1), 100878.

Cui H, et al. (2023) STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma. *Cancer immunology, immunotherapy : CII*, 72(5), 1315.